Menstrual Bleeding During Cardiovascular Antithrombotic Therapy: A Prospective Paired Clinical Follow-Up Study
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background: Menstrual changes during antithrombotic therapy for cardiovascular disease remain incompletely characterized. Methods: In a prospective observational cohort, we compared enrollment and follow-up menstrual assessments from 50 menstruating women treated for cardiovascular indications, including atrial fibrillation/flutter and coronary disease. We assessed within-person changes in menstrual-cycle classification and bleeding duration, together with bleeding-related documentation, healthcare visits, and absences. Results: The proportion with an abnormal cycle classification increased by 12.0 percentage points (95% CI, 2.0–22.6; 50 pairs), and the proportion reporting menses lasting at least 8 days increased by 12.5 percentage points (95% CI, 2.1–24.8; 48 pairs). For each outcome, six women newly met the definition and none ceased to meet it (exact McNemar p = 0.031). A documentation-based bleeding indicator was present in 17 of 46 evaluable women (37.0%). Menstrual-related healthcare visits and absences were reported by 13 and 6 women, respectively. Comparisons across treatment groups were exploratory because groups were small and differed by cardiovascular indication. Conclusions: Menstrual changes and related healthcare use and absences were observed during cardiovascular antithrombotic care. Routine assessment of menstrual symptoms may help identify women who need further evaluation and support.
DOI: 10.3390/jcdd13110606
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,258
Awards: G2230707412, G9001396325
OpenAlex ID: W7223549061
